Challenges In Developing CNS (Central Nervous System) Targeted Drugs
Drug discovery entails a process commencing from an idea to a product. This translational process is much more complex in developing technologies for the central nervous system. The complexity of central nervous system diseases, etiology, pathophysiology, disease-model limitations and target-organ exposure [the BBB], coupled with slow healing capacity, markedly adds to the list of developmental challenges.
The drug development process today aims to improve early attrition rates due to poor efficacy and lack of predictive toxicology. Early integration of target validation tools is essential in the modern CNS drug development process. Technology evaluation in pathophysiology-relevant animal models is critical to early internal decision-making processes.
During the early stages of drug development the technology evaluation in animal models is carefully considered and weight is given to model relevancy and species dependency. This is further complicated by the lack of existing animal models that mimic any given human CNS disorder adequately. The paucity of existing disease modifying agents, such as in the Parkinson's disease, multiple sclerosis disease and in strokes, only serves as a testament to the complexity of developing CNS (central nervous system) targeted drugs.
The search for disease modifying agents needs a strong basis of well established animal models that will enable to study very accurately the effect of new substances on the central nervous system.
Such models are created by companies that expertise in testing those new drugs for the pharmacological industry and providing them the input that can prevent mistakes that will harm human beings.
Drug discovery entails a process commencing from an idea to a product. This translational process is much more complex in developing technologies for the central nervous system. The complexity of central nervous system diseases, etiology, pathophysiology, disease-model limitations and target-organ exposure [the BBB], coupled with slow healing capacity, markedly adds to the list of developmental challenges.
The drug development process today aims to improve early attrition rates due to poor efficacy and lack of predictive toxicology. Early integration of target validation tools is essential in the modern CNS drug development process. Technology evaluation in pathophysiology-relevant animal models is critical to early internal decision-making processes.
During the early stages of drug development the technology evaluation in animal models is carefully considered and weight is given to model relevancy and species dependency. This is further complicated by the lack of existing animal models that mimic any given human CNS disorder adequately. The paucity of existing disease modifying agents, such as in the Parkinson's disease, multiple sclerosis disease and in strokes, only serves as a testament to the complexity of developing CNS (central nervous system) targeted drugs.
The search for disease modifying agents needs a strong basis of well established animal models that will enable to study very accurately the effect of new substances on the central nervous system.
Such models are created by companies that expertise in testing those new drugs for the pharmacological industry and providing them the input that can prevent mistakes that will harm human beings.
For more information about the evaluation of CNS-targeted drugs, and about working with animal models for the drug industry please refer to the PharmaSeed CRO company website and read more about our bio services.
Article Source: http://EzineArticles.com/?expert=Bobert_Richardson 
No comments:
Post a Comment